LONDON – In the rush to test drugs against COVID-19, clinical trials in other indications are starting to be interrupted by the strains on health care systems and the fact that many potential patients are those most at risk from the effects of the novel coronavirus.
With medical researchers across the globe adjusting to the far-reaching impacts of COVID-19, commercial and academic trialists are taking action to protect essential studies. Regulators, too, are now joining the effort in a more concerted way, with the FDA issuing new guidance for industry, investigators and institutional review boards on conducting clinical trials during the pandemic.
Randomized trials of the broad-spectrum antiviral favipiravir, marketed as an anti-influenza treatment by Fujifilm Holdings Corp., have shown "obvious efficacy" against COVID-19, according to Zhang Xinmin, head of the China National Center for Biotechnology Development.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Ambu, ATTC, Biointellisense, Biomerica, Bio-Techne, Centogene, Clinical Laserthermia Systems, Dover, Em-tec, Llamasoft, MeMD, Myriad Genetics, Oxford Nanopore Technologies, Pacific Biosciences of California, Parallax Health Sciences, Qiagen, Rewalk Robotics, Startx, Tomi Environmental Solutions, Tabula Rasa Healthcare, Windgo.
With the high need for ventilators in the face of COVID-19, Ventec Life Systems, of Bothell, Wash., is stepping up with its multifunction ventilator, known as VOCSN, for ventilation, oxygen, cough, suction and nebulization.
Google sister company Verily Life Sciences LLC has been under an unprecedented amount of scrutiny since it was promoted over the weekend by President Donald Trump as responsible for a nationwide information and testing program for the emerging novel coronavirus.
BEIJING – One day after the U.S. began the first human trial of an mRNA vaccine candidate for COVID-19 on March 16, China said Tuesday evening that it had approved the first clinical trial of a vaccine candidate developed by domestic researchers.